Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
Updates in Pediatric Rheum-Derm: Pathogenesis and New Treatments for JDM, Lupus, and Morphea
Description
This talk reviewed recent updates in pediatric rheum-dermatology, using Taylor Swift album tracks as a framing device, and focused on juvenile dermatomyositis (JDM), lupus, and morphea. It emphasized that all three diseases are multifactorial but share important immune pathways, especially interferon signaling and the JAK-STAT axis. For JDM, the speaker highlighted new insights into genetics such as low C4 copy number, UV- and viral-triggered disease, COVID-19 as a potential trigger, and the growing importance of myositis-specific antibodies like TIF1-gamma, NXP2, and MDA5 for phenotype and prognosis. For lupus, rare genetic mutations contribute but do not fully explain disease, and interferons remain central, with environmental triggers like viruses and light also playing a role. For morphea, pathogenesis involves environmental and epigenetic factors, fibroblast-driven fibrosis, and emerging evidence that interferons and genes such as MMP9 may contribute. The treatment section covered traditional therapies such as steroids, methotrexate, and mycophenolate, then moved to newer targeted options including JAK inhibitors, TYK2 inhibitors such as deucravacitinib, brepocitinib, anifrolumab, anti-interferon-beta therapy, and even CAR T-cell therapy in refractory cases. The talk closed by stressing that these advances are changing care and that collaboration with rheumatology and other specialists is essential.
View moreConclusions
- Across juvenile dermatomyositis, lupus, and morphea, interferon-driven immune dysregulation appears to be a central pathogenic theme.
- Juvenile dermatomyositis is multifactorial, with genetics, environmental triggers, viral infections, and myositis-specific autoantibodies all contributing to disease expression and prognosis.
- Certain myositis-specific antibodies help predict JDM phenotypes and are associated with more severe outcomes such as interstitial lung disease, refractory disease, and mortality.
- Cutaneous lupus subtypes differ in their risk of progression to systemic lupus, with acutely cutaneous disease carrying greater systemic risk than localized discoid disease.
- Rare genetic mutations and interferonopathies explain only part of juvenile SLE, indicating that additional environmental and immune factors are important.
- Localized scleroderma or morphea is also multifactorial, with epigenetic, vascular, immune, and fibrotic pathways all contributing to disease.
- Interferon signaling is relevant in morphea as well as lupus and dermatomyositis, supporting it as a broader target across pediatric rheum-derm disease.
- Mycophenolate mofetil may be similarly effective to methotrexate for juvenile localized scleroderma while being better tolerated.
- Targeted therapies that inhibit JAK-STAT, TYK2, or interferon pathways are emerging as promising options for refractory dermatomyositis and lupus.
- Anifrolumab and anti-IFN-beta agents show early promise for refractory disease, but much of the evidence remains limited to trials and case reports.
- CAR-T cell therapy is an exciting experimental approach that has shown dramatic improvement in refractory SLE and even a reported case of refractory juvenile dermatomyositis.
- Combined pediatric rheumatology-dermatology clinics improve patient care and are valued for education, coordination, and multidisciplinary collaboration.
- Overall, the presentation concludes that better understanding of interferon biology is translating into increasingly precise therapies for refractory pediatric rheum-derm disease.
- Cass NJ, Sabbagh SE, Kim H. Updates in juvenile dermatomyositis: pathogenesis and therapy. Curr Opin Rheumatol. 2025 Nov 1;37(6):445-456.#10.1097/bor.0000000000000816
- Basu S, Dodi A, Banerjee S, Vignes P. Juvenile Dermatomyositis: An Update of the Immunopathogenesis, Clinical Features, and Management. Indian Journal of Rheumatology, 2020.#10.1177/09733698251405036
- Liquidano-Perez E, Garcia-Romero M, Yamazaki-Nakashimada M, et al. Juvenile Dermatomyositis Triggered by SARS-CoV-2. Pediatric Neurology, 2021; 121, 26-27.#10.1016/j.pediatrneurol.2021.05.011
- Basu S, Dood A, Banerjee S, Vignesh P. Juvenile Dermatomyositis: An Update of the Immunopathogenesis, Clinical Features, and Management. Indian Journal of Rheumatology. 2026;0(0).#10.1177/09733698251405036
- Kurtzman DJB, Vleugels RA. Anti-melanoma differentiation-associated gene 5 (MDA5) dermatomyositis: A concise review with an emphasis on distinctive clinical features. J Am Acad Dermatol. 2018 Apr;78(4):776-785.#10.1016/j.jaad.2017.12.010
- Sherman, M.A., Noroozi Farhadi, P., Pah, K., et al. Childhood Myositis Heterogeneity Collaborative Study Group (2024), Myositis Associated Autoantibodies in Patients With Juvenile Myositis Are Associated With Refractory Disease and Mortality. Arthritis Rheumatol, 76: 963-972.#10.1002/art.42813
- Childs B, Merola JF: From the Masterclasses in Dermatology 2025 Meeting: Practical Approaches to Cutaneous and Systemic Lupus for Dermatologists. J Clin Aesthet Dermatol. 2025 Oct;18(10):40-47.
- Smith EMD, Lythgoe H, Midgley A, Beresford MW, Hedrich CM. Juvenile-onset systemic lupus erythematosus: Update on clinical presentation, pathophysiology and treatment options. Clin Immunol. 2019;203:108274.#10.1016/j.clim.2019.108274
- Li, S.C., Zheng, RJ. Overview of Juvenile localized scleroderma and its management. World J Pediatr 16, 5–18 (2020).#10.1007/s12519-019-00320-9
- Natalia Vasquez-Caizares, Suzanne C. Li, Juvenile Localized Scleroderma: Updates and Differences from Adult-Onset Disease, Rheumatic Disease Clinics of North America, Volume 47, Issue 4, 2021, Pages 737-755.#10.1016/j.rdc.2021.07.014
- Dignum T, Brandling-Bennett H. A consensus-based electronic medical record template for pediatric morphea patient visits. Pediatr Dermatol. 2024;41(3):131-133.#10.1111/pde.15699
- de Rosas EC, Wang JC, Ziegler CK, Torok KS. Methotrexate and Mycophenolate Mofetil and Clinical Response in Juvenile Localized Scleroderma. JAMA Dermatol. Published online January 28, 2026.#10.1001/jamadermatol.2025.5662
- Vleugels RA, Park JJ, Bauer Ventura L, et al. A Phase 3 Trial of Brepocitinib in Dermatomyositis. New England Journal of Medicine. Published online March 28, 2026.#10.1056/nejmoa2503531
- Jin, X., Han, L., Wang, L.L. et al. CAR-T cell therapy: new hope for systemic lupus erythematosus patients. Cell Mol Immunol 18, 2581–2582 (2021).#10.1038/s41423-021-00787-5
- Nicolà R, Merli P, Moran Alvarez P, et al. Autologous CD19-targeting CAR T cells in a patient with refractory juvenile dermatomyositis. Arthritis Rheumatol 2024; 76:1560–1565.#10.1002/art.42933